The estimated Net Worth of Hong Liang is at least $840 Thousand dollars as of 2 April 2020. Dr Liang owns over 4,000 units of Kodiak Sciences Inc stock worth over $321,510 and over the last 6 years he sold KOD stock worth over $518,280.
Dr has made over 5 trades of the Kodiak Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,000 units of KOD stock worth $169,360 on 2 April 2020.
The largest trade he's ever made was exercising 80,000 units of Kodiak Sciences Inc stock on 7 February 2019 worth over $83,200. On average, Dr trades about 19,167 units every 60 days since 2019. As of 2 April 2020 he still owns at least 130,166 units of Kodiak Sciences Inc stock.
You can see the complete history of Dr Liang stock trades at the bottom of the page.
Dr. Hong Liang is the Sr. VP of Discovery Medicine at Kodiak Sciences Inc.
Dr Liang is 49, he's been the Sr. VP of Discovery Medicine of Kodiak Sciences Inc since . There are 7 older and 4 younger executives at Kodiak Sciences Inc. The oldest executive at Kodiak Sciences Inc is Robert Profusek, 70, who is the Lead Independent Director.
Over the last 6 years, insiders at Kodiak Sciences Inc have traded over $15,919,920 worth of Kodiak Sciences Inc stock and bought 10,439,459 units worth $472,964,631 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bros. Advisors Lp667, L.P.B..., and Victor Perlroth. On average, Kodiak Sciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $393,170. The most recent stock trade was executed by John A. Borgeson on 15 June 2024, trading 5,494 units of KOD stock currently worth $13,570.
about kodiak kodiak is a high-science retinal medicines development company. we are aspiring to build a dominant global retina franchise. we are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. in our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. working at kodiak we are passionate about preventing blindness and improving health. we take pride in scientific and operational excellence. the curiosity, creativity, and courage of our team members drives our progress. we highly value this culture and support it every way we can. kodiak supports a vibrant and active lifestyle. we have a top benefits package. we are within walking distance to california avenue sh
Kodiak Sciences Inc executives and other stock owners filed with the SEC include: